Advertisement
Advertisement
U.S. Markets open in 2 hrs 16 mins
Advertisement
Advertisement
Advertisement
Advertisement

Aptorum Group Limited (APM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.5000+0.0400 (+1.63%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4600
Open2.4800
Bid0.0000 x 3000
Ask0.0000 x 2200
Day's Range2.4300 - 2.5000
52 Week Range2.0000 - 4.9400
Volume52,668
Avg. Volume134,309
Market Cap89.005M
Beta (5Y Monthly)-0.22
PE Ratio (TTM)12.50
EPS (TTM)0.2000
Earnings DateApr 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • Business Wire

    Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

    NEW YORK & LONDON & PARIS, October 19, 2021--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that it will hold its 2021 annual general meeting of shareholders at Meeting Room 06, 1/F, Building 1E, Hong Kong Science Park, N.T., Hong Kong at 8:00 p.m. Hong Kong Time on December 2, 2021 (7:00 a.m. Eastern Standa

  • Business Wire

    Aptorum Group Limited Interview to Air on Bloomberg U.S.

    NEW YORK & LONDON & PARIS, October 15, 2021--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, today announced that an interview with President Darren Lui will air on The RedChip Money Report® on Bloomberg TV Oct. 16 at 7 p.m. Eastern Time (ET).

  • Benzinga

    Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

    The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is a bioavailability/food effect study that will take four months to complete. The bioavailability/food effect study aims to compare the relative bioavailability of the newly developed SACT-1 pediatric formulation in healthy adult subjects. The above study will follow a planned Phase 1b/2a trial in pediatric patients with relapsed or refracto

Advertisement
Advertisement